Cilastatin

Subscribe to Selected New Research on Cilastatin

99 relevant articles (17 outcomes, 15 trials/studies) found for this Drug

Description: A renal dehydropeptidase-I and leukotriene D4 dipeptidase inhibitor. Since the antibiotic, IMIPENEM, is hydrolyzed by dehydropeptidase-I, which resides in the brush border of the renal tubule, cilastatin is administered with imipenem to increase its effectiveness. The drug also inhibits the metabolism of leukotriene D4 to leukotriene E4.

Also Known As:

Cilastatin Monosodium Salt; Cilastatin Sodium; MK 0791; MK-791; MK0791; 0791, MK; MK 791; MK791; Monosodium Salt, Cilastatin; Salt, Cilastatin Monosodium; Sodium, Cilastatin; 2-Heptenoic acid, 7-((2-amino-2-carboxyethyl)thio)-2-(((2,2-dimethylcyclopropyl)carbonyl)amino)-, (R-(R*,S*-(Z)))-

Relationship Network

Drug Context: Research Results

Organic Chemicals: 40

Hydrocarbons: 382

Cyclic Hydrocarbons: 2

Alicyclic Hydrocarbons: 1

Cycloparaffins: 3

Cyclopropanes: 1

Cilastatin: 99

imipenem-cilastatin: 523

N-acetylcilastatin

Lipids: 13315

Fatty Acids: 4660

Unsaturated Fatty Acids: 2221

Monounsaturated Fatty Acids: 150

Cilastatin: 99

imipenem-cilastatin: 523

N-acetylcilastatin

Experts

1.	Edwards, Steven J: 2 articles (03/2006 - 05/2005)
2.	Campbell, Helen E: 2 articles (03/2006 - 05/2005)
3.	Plumb, Jonathan M: 1 article (03/2006)
4.	Emmas, Cathy E: 1 article (05/2005)
5.	Naber, Kurt G: 1 article (02/2002)
6.	Salmen, Hans C: 1 article (02/2002)
7.	Savov, Orlin: 1 article (02/2002)
8.	Bruserud, O: 1 article (01/2000)

Related Diseases

1.	Infection 10/01/1997 - "The potent in vivo activity of BO-3482-cilastatin against such MRSA infections can be ascribed to the good in vitro anti-MRSA activity and improved pharmacokinetics in mice when BO-3482 is combined with cilastatin and to the bactericidal nature of the carbapenem." 05/01/1986 - "Based on the above results, MK-0787/MK-0791 appears to be effective against gynecological and obstetrical infections." 07/01/1986 - "Based on the above results, it can be concluded that MK-0787/MK-0791 is a safe and effective drug to use for the treatment of pediatric infections." 05/01/1986 - "It may be concluded that MK-0787/MK-0791 is useful for the treatment of obstetrical and gynecological infections." 05/01/1986 - "These results suggest that MK-0787/MK-0791 will be useful for the treatment of obstetric and gynecologic infections." Get all the results and reference details, order at left...
2.	Pyelonephritis 02/01/1984 - "The therapeutic efficacy of N-formimidoyl thienamycin alone or coadministered with MK0791, an inhibitor of renal dehydropeptidase-I, compared to methicillin in experimental pyelonephritis in rats was investigated" 02/01/2002 - "Piperacillin 2 g/tazobactam 0.5 g is as effective as imipenem 0.5 g/cilastatin 0.5 g for the treatment of acute uncomplicated pyelonephritis and complicated urinary tract infections." 07/01/1986 - "Twenty-four patients, including 1 with purulent meningitis, 1 with septicemia, 1 with pyothorax, 10 with bronchopneumonia, 7 with pyelonephritis and 4 with infections of cutaneous soft tissue were treated with MK-0787/MK-0791 at dose levels of over 100 mg/100 mg/kg/day with purulent meningitis and septicemia and 28.8 mg/28.8 mg-72.8 mg/72.8 mg/kg/day with other infections" Get all the results and reference details, order at left...
3.	Bacterial Infections (Bacterial Infection) 07/01/1986 - "From the present study, MK-0787/MK-0791 appears a safe and effective antibiotic when used in children with a variety of bacterial infections." 07/01/1986 - "The MK-0787/MK-0791 was administered to 13 children with bacterial infections" 07/01/1986 - "Thirty cases of bacterial infections were treated with MK-0787/MK-0791 at a daily dose of 40 to 222 mg/kg for 2.25 to 13 days" 06/01/1986 - "Four patients with bacterial infections were treated with MK-0787/MK-0791" 10/01/1987 - "In a randomized prospective study, 66 patients with serious bacterial infections--mainly lower respiratory tract infections--were treated with either imipenem plus cilastatin (32 patients) or ciprofloxacin (34 patients); 30 patients in each group were evaluable for efficacy" Get all the results and reference details, order at left...
4.	Chronic Kidney Failure (Chronic Renal Failure) 08/01/1984 - "The mean plasma half-life of cilastatin varied from 54 min in normals to 798 min in patients with end-stage renal failure" 08/01/1991 - "Removal of imipenem and cilastatin by hemodialysis in patients with end-stage renal failure." 10/01/2005 - "Total body clearance of imipenem during CRRT in patients suffering from acute renal failure was found to range between 89 and 149 ml/min. Total body clearance of cilastatin ranged between 9 and 32 ml/min. Total body clearance of both imipenem and cilastatin was reduced in patients with chronic renal failure" Get all the results and reference details, order at left...
5.	Urinary Tract Infections (Urinary Tract Infection) 04/01/1986 - "Overall clinical effectiveness rate judged by the criteria proposed by the Japanese UTI committee in 22 cases of chronic complicated urinary tract infection treated with MK-0787/MK-0791 was evaluated to be 86% including excellent in 6 cases, moderate in 13 cases and poor in 3 cases" 02/01/2002 - "Piperacillin 2 g/tazobactam 0.5 g is as effective as imipenem 0.5 g/cilastatin 0.5 g for the treatment of acute uncomplicated pyelonephritis and complicated urinary tract infections." 04/01/1986 - "MK-0787 was more active than CEZ, CMX and CPZ against all bacterial species except Proteus spp. Imipenem/cilastatin sodium (MK-0787/MK-0791) 500 mg/500 mg two times a day for 5 days was given to 31 cases of chronic complicated urinary tract infections and a case of acute prostatitis" Get all the results and reference details, order at left...
71 Diseases and 99 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Imipenem
2.	imipenem-cilastatin (Primaxin)
3.	dipeptidase (membrane dipeptidase)
4.	Piperacillin
5.	Sodium
6.	Clindamycin (Cleocin)
7.	thienamycin
8.	cefepime (Maxipime)
9.	tazobactam
10.	Metronidazole (Metric)
47 Drugs and Important Bio-Agents and 94 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Intensive Care (Surgical Intensive Care)
3.	Hysterectomy
4.	Renal Dialysis (Hemodialysis)
4 Therapies and Procedures and 7 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>